Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Immunological aspects of cancer chemotherapy.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.

Nat Rev Immunol. 2008 Jan;8(1):59-73. Review.

PMID:
18097448
2.

Protective cancer immunotherapy: what can the innate immune system contribute?

Schmitz F, Heit A.

Expert Opin Biol Ther. 2008 Jan;8(1):31-43. Review.

PMID:
18081535
3.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.

Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.

PMID:
17704786
4.

Impact of the human papilloma vaccine on cervical cancer.

Chan JK, Berek JS.

J Clin Oncol. 2007 Jul 10;25(20):2975-82. Review.

PMID:
17617529
5.

Trastuzumab--mechanism of action and use in clinical practice.

Hudis CA.

N Engl J Med. 2007 Jul 5;357(1):39-51. Review. No abstract available.

PMID:
17611206
6.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
7.

More than one reason to rethink the use of peptides in vaccine design.

Purcell AW, McCluskey J, Rossjohn J.

Nat Rev Drug Discov. 2007 May;6(5):404-14. Review.

PMID:
17473845
8.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.

Nat Rev Cancer. 2007 May;7(5):345-56. Review.

PMID:
17457302
9.

Chemical adjuvants for plasmid DNA vaccines.

Greenland JR, Letvin NL.

Vaccine. 2007 May 10;25(19):3731-41. Epub 2007 Feb 20. Review.

PMID:
17350735
10.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
11.

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.

Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53.

12.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team.

Lancet. 2007 Jan 6;369(9555):29-36.

PMID:
17208639
13.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
14.

Calreticulin exposure dictates the immunogenicity of cancer cell death.

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G.

Nat Med. 2007 Jan;13(1):54-61. Epub 2006 Dec 24.

PMID:
17187072
15.

Dendritic cell-based immunotherapy.

Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):377-413. Review.

PMID:
17169781
16.

Heat shock protein vaccines: from bench to bedside.

Binder RJ.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):353-75. Review.

PMID:
17169780
17.

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

Hege KM, Jooss K, Pardoll D.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):321-52. Review.

PMID:
17169779
18.

Overview of tumor cell-based vaccines.

Copier J, Dalgleish A.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):297-319. Review.

PMID:
17169778
19.

Inhibitory effects of B cells on antitumor immunity.

Inoue S, Leitner WW, Golding B, Scott D.

Cancer Res. 2006 Aug 1;66(15):7741-7.

20.

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

Siddiqui MA, Perry CM.

Drugs. 2006;66(9):1263-71; discussion 1272-3. Review.

PMID:
16827602

Supplemental Content

Support Center